Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the ...

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

Novo Nordisk CEO Mike Doustdar tells CNBC he expects to close the company's takeover offer for Metsera. This as the company ...

Tokyo's benchmark Nikkei 225 index has fallen more than 4% and other shares in Asia also sank after a retreat on Wall Street ...

Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss ...

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after federal regulators narrowed recommendations on who should get them.

Eli Lilly and Novo Nordisk are expected to announce deals with the Trump administration to cut prices of their weight-loss ...

Stocks fell on Wall Street Tuesday, pulled down by losses in the same big tech companies that have been the main drivers of ...

Global stocks mostly fell Tuesday as investors weighed the recent tech rally on Wall Street against growing fears of an AI ...

Go behind the scenes at CrimeCon 2025, where true crime meets reality TV in a unique look at fans, experts, and storytelling.

While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.